TIDMIMM

RNS Number : 1578J

Immupharma PLC

28 March 2018

28 March 2018

ImmuPharma PLC

("ImmuPharma" or the "Company")

Appointment of Joint Broker

ImmuPharma PLC (AIM: IMM.L), the specialist drug discovery and development company, is pleased to announce that it has with immediate effect appointed Bryan, Garnier & Co. Limited as its joint corporate broker to act alongside Northland Capital Partners who remain the Company's Nominated Adviser and joint corporate broker.

Tim McCarthy, Chairman of ImmuPharma, commented: "We welcome Bryan Garnier as Joint Broker. Bryan Garnier provides ImmuPharma with deep healthcare expertise and pan European broking capability, to support the Company as we progress towards commercialisation."

Olivier Garnier, Founder and Managing Partner of Bryan, Garnier & Co. commented: "We are delighted to be appointed and we look forward to working with the Company at this very exciting time."

 
 For further information please contact: 
                                                      + 44 (0) 20 
  ImmuPharma plc (www.immupharma.org)                  7152 4080 
  Tim McCarthy, Chairman 
  Lisa Baderoon, Head of Investor Relations           + 44 (0) 7721 
   Twitter: @immupharma                                413496 
 
  Northland Capital Partners Limited (NOMAD & 
   Joint Broker) 
   David Hignell, Dugald Carlean, Jamie Spotswood, 
   Corporate Finance                                  +44 (0)20 3861 
   Rob Rees, Corporate Broking                         6625 
  Bryan, Garnier & Co. (Joint Broker) 
   Phil Walker, Corporate Finance                     +44 (0)20 7332 
   Dominic Wilson, Sales                               2500 
 
 
 
 Notes to Editors 
 
 ImmuPharma PLC 
 
 ImmuPharma is a pharmaceutical development company listed since 
 2006 on AIM of the London Stock Exchange (AIM: IMM), focusing 
 on developing novel medicines with high sales potential in 
 specialist markets with serious unmet need. ImmuPharma is led 
 by a commercially focused Board and management team with extensive 
 experience. 
 
 Lupuzor(TM) 
 
 Lupuzor(TM) (also referred to as Forigerimod, or P140) is ImmuPharma's 
 lead compound and a potential treatment for lupus (or Systemic 
 Lupus Erythematosus), a chronic, potentially life-threatening 
 auto-immune disease. Lupuzor(TM) has a novel mechanism of action 
 aimed at modulating the body's immune system so that it does 
 not attack healthy cells, and avoids causing adverse side effects. 
 It has the potential to halt the progression of the disease 
 in a substantial proportion of patients. 
 
 Lupuzor(TM) has been granted Fast Track status by the US FDA 
 and approval to start Phase III under Special Protocol Assessment 
 (SPA). This SPA was subsequently amended due to its strong 
 safety and efficacy profile to allow for a reduced number of 
 patients in the pivotal Phase III trial thereby reducing the 
 projected cost and time of development considerably. 
 
 The pivotal Phase III clinical study is entitled "A 52-Week, 
 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 
 Study to Evaluate the Efficacy and Safety of a 200-mcg Dose 
 of IPP-201101 Plus Standard of Care in Patients With Systemic 
 Lupus Erythematosus". It is a pivotal study designed to demonstrate 
 the safety and efficacy of IPP-201101 and as a last step prior 
 to the filing of the drug for approval with the US Food & Drug 
 Administration ("FDA") and the European Medicines Agency ("EMA"). 
 For more information please visit: 
 https://clinicaltrials.gov/ct2/show/NCT02504645 
 
 Commercial Opportunity 
 There are an estimated five million people globally suffering 
 from Lupus, with approximately 1.5 million patients in the 
 US, Europe and Japan (Source: Lupus Foundation of America). 
 Current 'standard of care' treatments, including steroids and 
 immunosuppressants, can potentially have either serious side 
 effects for patients or limited effectiveness, with over 60% 
 of patients not adequately treated. GSK's Benlysta is the first 
 Lupus drug approved in over 50 years and paves the path to 
 market for Lupuzor(TM). Based on conservative estimates, and 
 taking into account that Benlysta is priced currently at approximately 
 $30,000 per patient per year, Lupuzor(TM) would be entering 
 a market with the potential for multi-billion dollar sales. 
 For more information on Lupuzor(TM) please visit: www.lupuzor.com 
 
 
 About Bryan Garnier & Co. 
 
 Bryan, Garnier & Co is a European, full service growth-focused 
 independent investment banking partnership founded in 1996. 
 The firm provides equity research, sales and trading, private 
 and public capital raising as well as M&A services to growth 
 companies and their investors. It focuses on key growth sectors 
 of the economy including Technology, Media & Telecoms, Healthcare, 
 Smart Industries & Energy, Consumer, Brands & Retail and Business 
 Services. Bryan, Garnier & Co is a fully registered broker 
 dealer authorized and regulated by the FCA in Europe and the 
 FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, 
 with additional offices in Paris, Munich, Zurich and New York. 
 The firm is a member of the London Stock Exchange and Euronext.

This information is provided by RNS

The company news service from the London Stock Exchange

END

APPUBAKRWNAOUAR

(END) Dow Jones Newswires

March 28, 2018 02:01 ET (06:01 GMT)

Immupharma (LSE:IMM)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Immupharma Charts.
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Immupharma Charts.